MAHAFFY PATRICK J 4

4 · Clovis Oncology, Inc. · Filed Mar 3, 2021

Form 4

Period: 2021-03-01

DirectorPresident and CEO

Transactions

Award
Stock Option (right to buy)
2021-03-01+80,000→ 80,000 total
Exercise: $6.23Exp: 2031-03-01→ Common Stock (80,000 underlying)
Award
Stock Option (right to buy)
2021-03-01+40,000→ 40,000 total
Exercise: $6.23Exp: 2031-03-01→ Common Stock (40,000 underlying)
Award
Stock Option (right to buy)
2021-03-01+220,000→ 220,000 total
Exercise: $6.23Exp: 2031-03-01→ Common Stock (220,000 underlying)
Award
Stock Option (right to buy)
2021-03-01+40,000→ 40,000 total
Exercise: $6.23Exp: 2031-03-01→ Common Stock (40,000 underlying)

Footnotes (4)

[F1]The option shall vest as to 25% of the shares on March 1, 2022, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
[F2]The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2021 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 8, 2020.
[F3]The option shall vest upon the selection of an alpha-emitter agent for use in the study of the Company's product candidate FAP-2286 on or before December 31, 2021.
[F4]The option shall vest upon the enrollment of three dose cohorts in the Company's LuMIERE study on or before December 31, 2021.

Documents

1 file